

AYRES JOHN C
Form 3
January 09, 2019

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â AYRES JOHN C
(Last) (First) (Middle)

C/O ARATANA
THERAPEUTICS, INC., Â 11400
TOMAHAWK CREEK
PARKWAY, SUITE 340
(Street)

LEAWOOD, Â KS Â 66211
(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
01/04/2019

3. Issuer Name and Ticker or Trading Symbol
ARATANA THERAPEUTICS, INC. [PETX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

____ Director ____ 10% Owner
__X__ Officer ____ Other
(give title below) (specify below)

SEE REMARKS

6. Individual or Joint/Group Filing(Check Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

98,091

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: AYRES JOHN C - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (1)	11/12/2023	Common Stock	66,667	\$ 20.4	D	Â
Stock Option (Right to Buy)	Â (2)	01/12/2024	Common Stock	20,000	\$ 18.42	D	Â
Stock Option (Right to Buy)	Â (3)	01/28/2025	Common Stock	25,000	\$ 17.18	D	Â
Stock Option (Right to Buy)	Â (4)	01/21/2026	Common Stock	70,000	\$ 3.14	D	Â
Stock Option (Right to Buy)	Â (5)	01/12/2027	Common Stock	37,500	\$ 8.02	D	Â
Stock Option (Right to Buy)	Â (6)	01/24/2028	Common Stock	60,000	\$ 4.83	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AYRES JOHN C C/O ARATANA THERAPEUTICS, INC. 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 LEAWOOD,Â KSÂ 66211	Â	Â	Â SEE REMARKS	Â

Signatures

/s/ John C. Ayres 01/09/2019

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Fully vested as of November 13, 2017.

(2) Fully vested as of January 13, 2018.

(3) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2016 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2019, subject to continued service with the Issuer through the applicable vesting dates.

(4) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates.

Edgar Filing: AYRES JOHN C - Form 3

- (5) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates.

- (6) Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates.

Â

Remarks:

TheÂ ReportingÂ PersonÂ isÂ VPÂ -Â CorporateÂ Operations,Â GeneralÂ CounselÂ andÂ Secretary.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.